Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease

被引:28
作者
Depboylu, C
Du, YS
Müller, U
Kurz, A
Zimmer, R
Riemenschneider, M
Gasser, T
Oertelf, WH
Klockgether, T
Dodel, RC
机构
[1] Univ Bonn, Dept Neurol, D-53105 Bonn, Germany
[2] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 47405 USA
[3] Univ Giessen, Inst Human Genet, Giessen, Germany
[4] Tech Univ Munich, Dept Psychiat, D-8000 Munich, Germany
[5] Univ Tuebingen, Dept Neurol, Hertie Inst Brain Res, Tubingen, Germany
[6] Univ Marburg, Dept Neurol, D-35032 Marburg, Germany
关键词
dementia; Alzheimer's disease; inflammation; pro-inflammatory; polymorphism; cytokine; interleukin;
D O I
10.1016/S0304-3940(03)00231-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
There is increasing evidence that immune mechanisms are involved in the pathogenesis of Alzheimer's disease (AD). Recently, polymorphisms of the interleukin (IL)-1 and IL-6 genes were found to be associated with late-onset AD. The immunoregulatory IL-10 downregulates synthesis of pro-inflammatory cytokines such as IL-1. Current evidence suggests that some polymorphisms in the IL-10 promoter may have functional effects on IL-10 transcription. A total of 406 German AD patients (mean age 70.2 +/- 10.0 years, range 50-95 years, 42% female) and 251 unrelated non-demented control subjects (mean age 66.8 +/- 10.6 years, range 50-93 years, 38% female) were investigated for the presence of three polymorphisms in the IL-10 promoter region (-1087A/G, - 824C/T, - 597C/A). No significant differences in the allelic distribution of the analyzed IL-10 polymorphisms have been found between AD patients and controls. We conclude that polymorphisms in the IL-10 promoter region do not increase the risk of developing AD. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:132 / 134
页数:3
相关论文
共 16 条
[1]  
[Anonymous], ICD 10 CLASS MENT BE
[2]   Neuroinflammation and Alzheimer's disease:: critical roles for cytokine/Aβ-induced glial activation, NF-κB, and apolipoprotein E -: Commentary [J].
Bales, KR ;
Du, Y ;
Holtzman, D ;
Cordell, B ;
Paul, SM .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :427-432
[3]  
Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO
[4]  
2-Y
[5]   Association of an interleukin 1α polymorphism with Alzheimer's disease [J].
Du, Y ;
Dodel, RC ;
Eastwood, BJ ;
Bales, KR ;
Gao, F ;
Lohmüller, F ;
Müller, U ;
Kurz, A ;
Zimmer, R ;
Evans, RM ;
Hake, A ;
Gasser, T ;
Oertel, WH ;
Griffin, WST ;
Paul, SM ;
Farlow, MR .
NEUROLOGY, 2000, 55 (04) :480-483
[6]  
GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276
[7]  
Hulkkonen J, 2001, ARTHRITIS RHEUM, V44, P176, DOI 10.1002/1529-0131(200101)44:1<176::AID-ANR23>3.0.CO
[8]  
2-K
[9]  
MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
[10]   APOE genotype predicts when -: not whether -: one is predisposed to develop Alzheimer disease [J].
Meyer, MR ;
Tschanz, JT ;
Norton, MC ;
Welsh-Bohmer, KA ;
Steffens, DC ;
Wyse, BW ;
Breitner, JCS .
NATURE GENETICS, 1998, 19 (04) :321-322